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Abstract Heteroaryl ortho-phenoxyethylamines have been extensively
employed in medicinal chemistry as privileged scaffolds for the design
of highly potent and selective ligands. Herein an efficient, fast, and gen-
eral method for the synthesis of heteroaryl phenoxyethylamines via Su-
zuki cross-coupling is reported. This approach offers the opportunity to
obtain a large variety of biaryls incorporating five-membered (thio-
phene, furan, thiazole, pyrazole, imidazole) or six-membered (pyridine,
pyrimidine) heteroaromatic rings for appropriate libraries of ligands. All
the compounds presented here have never been synthesized before
and a full structural characterization is given.
Key words C–C coupling, heterocycles, palladium, Suzuki–Miyaura
cross-coupling, building blocks
Heteroaryl ortho-phenoxyethylamines have been exten-
sively employed in medicinal chemistry as privileged scaf-
folds for the design of highly potent and selective ligands
(Figure 1) for glycine transporter GlyT1 (1),1 α1 adrenergic
receptor 2,2 DNA topoisomerases 3,3 AMPA receptor 4,4 and
5-HT2A receptor 5.5,6 Moreover, Trifenagrel (6), a potent in-
hibitor of arachidonate-induced platelets aggregation,7
moPhpC 7, fluorescent pyrrolocytosine nucleobases de-
signed for tight binding to guanine,8 and some 2,3- and 3,4-
diarylfurans, for example, 89 with anti-implantation activi-
ty, belong to this versatile class of heteroaryl ortho-phe-
noxyethylamines.
Despite the important role of these chemical entities in
several fields of medicinal chemistry, a general method for
heteroaryl ortho-phenoxyethylamine synthesis has not yet
been reported. From a practical point of view, the assembly
of these building blocks could be achieved via cross-cou-
pling of two monocyclic units. Among the various method-
ologies available,10 the Suzuki–Miyaura reaction, one of the
most popular and powerful methods for the joining of aryl–
aryl and aryl–heteroaryl moieties, was chosen.11 Thanks to
its compatibility with a variety of functional groups, the
stability, commercial availability, and low toxicity of a wide
range of boronic starting materials, along with the ease of
working up the reaction mixtures, this reaction has found
many applications, in both research laboratories and large-
scale industrial processes.12
In this work, we describe the synthesis of several het-
eroaryl ortho-phenoxyethylamines via Suzuki cross-cou-
pling. This approach offers the opportunity to obtain a large
variety of biaryls incorporating five-membered electron-
rich (thiophene, furan), six-membered electron-poor (pyri-
dine, pyrimidine), or five-membered rings with two het-
eroatoms (thiazole, pyrazole, imidazole) for appropriate li-
braries of ligands.
In an attempt to find a convenient and versatile strategy
to build the ortho-substituted biaryl scaffold, we took into
account several factors: i) the different nature of the het-
erocycle to be coupled: electron-rich or electron-poor; ii)
the presence of sterically hindered ortho-substituted sub-
strates; iii) the presence of LiAlH4-sensitive heterocycles
such as pyrimidine; iv) the presence of heteroatoms such as
sulfur or nitrogen that may drastically reduce the yields of
some steps (i.e., reduction) due to the poisoning of the cata-
lyst; and v) the opportunity to start from a common pre-
cursor (nitrile or masked amine) by inserting the structural
diversity in the last step of the synthesis.
It is well known that the optimal conditions for Suzuki
coupling is the electron-poor nature of aryl halide and the
electron-rich nature of arylboronic acid. Keeping this in
mind, we designed a synthetic approach, employing a com-
mon key intermediate 9, which directly underwent Suzuki© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2015, 47, A–J
BL. I. Manasieva et al. PaperSyn thesiscoupling in the case of electron-rich substrates or was con-
verted into the corresponding pinacolboronic ester 10 and
then coupled with the electron-poor aryl halide, as de-
scribed in Scheme 1.
Alkylation of 2-iodophenol in the standard conditions
reported for the Williamson reaction provided the aryl io-
dide 9 in high yield (89%). Suzuki coupling of 2-(2-iodophe-
noxy)acetonitrile (9) with an aryl pinacolboronic ester has
recently been described.13 However, while many references
relating to the coupling of the o-iodoanisole or higher ho-
mologues, such as 9, with a variety of boronic acids/esters
have been reported,13,14 to the best of our knowledge, there
are no examples of unsubstituted o-iodoanisole coupled
with 2-thiophenyl- or 2-furanylboronic acids.
Figure 1  Structures of heteroaryl ortho-phenoxyethylamine-based compounds
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Scheme 1  Reagents and conditions: i) bromoacetonitrile, K2CO3, 18-crown-6 ether, acetone, 55 °C, 150 W, 1 h, 89%; ii) see Table 1, entry 8, 95%; iii) 
ArB(OH)2 (for 11, 12) or ArBr (for 13, 14), Na2CO3, Pd(PPh3)4, toluene–EtOH (3:1 v/v), 90 °C, 8 h, 70% (11), 93% (12), 68% (13), 40% (14); iv) LiAlH4, 
Et2O, 0 to 25 °C, 1 h, 92% (15), 60% (16), 79% (17), 79% (18).
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arylfuran or -thiophene derivatives, via palladium-cata-
lyzed coupling, starting from the corresponding electroni-
cally activated boronic acids. It is known that 2-thiophenyl-
or 2-furanylboronic acids easily undergo deboronation un-
der the basic conditions of the Suzuki–Miyaura coupling.15
Here we have developed an optimized procedure in which
the degree of deboronation is negligible or absent, as attest-
ed by the good/excellent yields reported for heterobiaryls
11 and 12 (70 and 93%, respectively).
We found that the best reaction conditions were
tetrakis(triphenylphosphine)palladium(0) as a catalyst in
combination with the cheap base potassium carbonate; a
mixture of toluene and ethanol was more effective than
DMF as a reaction solvent, as attested by the higher yields,
compared to those previously reported.13 However, when a
mixture of toluene–ethanol (1:1 v/v) was employed, along
with the desired product 11 (55% yield), the corresponding
ethyl ester (14%) was isolated, due to the alcoholysis of the
nitrile. Since the presence of an alcohol may improve wa-
ter/toluene miscibility and consequently the activation of
the boronic acid to boronate by the hydroxyl anion, in order
to prevent the formation of the ethyl ester, the amount of
ethanol was lowered (toluene–ethanol, 3:1 v/v). Under
these conditions the ester was found in trace amounts and
11 was isolated in good yield (70%). By using the same cou-
pling conditions described for 11, the 2-furanyl derivative
12 was synthetized in excellent yield (93%) without any op-
timization steps.
These coupling conditions allow a variety of heterobiar-
yls to be obtained in good/high yields, starting from the
corresponding electron-rich boronic acids, even in the pres-
ence of a base sensitive group.
Conversely, since it is known that Suzuki reactions of
electron-deficient 2-heterocyclic boronates, such as 2-pyr-
idyl, generally give low conversions,16 13 was obtained by
reacting the corresponding commercially available bromo
derivative with the pinacolboronic ester 10. Pinacol boro-
nates are a very attractive synthon since they are air-, mois-
ture-, temperature-, and chromatography-stable. However,
for ortho-substituted substrates, as for 9, the synthesis of
the corresponding boronic ester provides very low yields
and also requires harsh conditions, due to the steric hin-
drance created by the ortho-substituent.17 In an attempt to
obtain the pinacolboronic intermediate 10 in high yields,
the results published by several groups concerning the Su-
zuki coupling of sterically hindered substrates were investi-
gated.17,18 In fact, it has been reported that the employment
of a phosphine ligand might improve the borylation of or-
tho-substituted aryl halides under mild conditions.
A series of commercially available palladium-based cat-
alysts such as tetrakis(triphenylphosphine)palladium(0)
[Pd(PPh3)4], tris(dibenzylideneacetone)dipalladium(0)
[Pd2(dba)3], and palladium(II) acetate [Pd(OAc)2] alone or in
combination with palladium ligands such as JohnPhos [1,1′-
biphenyl]-2-yl-di-tert-butylphosphine or Cy-JohnPhos [(2-
biphenyl)dicyclohexylphosphine], were considered.
In Table 1, the optimization of the borylation reaction,
including solvent (Et3N or DMF) and reaction time, is
shown. The optimal reaction conditions were found to be
associated with the employment of Pd(OAc)2 and a biphen-
ylphosphine ligand. In particular, a molar ratio of 4:1 ligand
(Cy-JohnPhos) to catalyst [Pd(OAc)2] afforded 10 with the
highest yield (95%) and the lowest reaction time (2 h) (Table
1, entry 8).
Table 1  Optimization of the Borylation Reaction of 2-(2-Iodophe-
noxy)acetonitrile (9)a
Thus, the pinacolboronic ester 10 was allowed to react
with 2-bromo- or 3-bromopyridine using the same cou-
pling conditions described for 11, to afford the pyridinyl de-
rivatives 13 and 14 in good (68%) and moderate (40%)
yields, respectively. The same conditions were successfully
applied for the coupling of highly electronically deactivated
aryl halides, such as bromopyrimidine (data not shown).
Entry Pd catalyst Temp 
(°C)
Time 
(h)
10 Yield 
(%)b
1 5 mol% Pd(PPh3)4 100 10  0
2 10 mol% Pd(PPh3)4 100 10  0
3 5 mol% Pd2dba3 100 10  0
4 10 mol% Pd2dba3 100 10  0
5 5 mol% Pd(OAc)2, 10 mol% B 100 20 33
6 5 mol% Pd(OAc)2, 20 mol% B 100 20 54
7 5 mol% Pd(OAc)2, 10 mol% C 100  5 82
8 5 mol% Pd(OAc)2, 20 mol% C 100  2 95
a Reagents and conditions: Et3N (4 equiv), A (3 equiv).
b Isolated yields after flash chromatography.
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good/high yields (60–92%) after reduction of the nitriles
11–14 by LiAlH4. Unfortunately, in the case of pyrimidinyl
biaryls the use of highly reactive reducing agents, such as
LiAlH4, resulted in the degradation of the pyridimidine moi-
ety.
Investigation with thiazole analogues led to similar re-
sults. This side-reaction can be explained by the low aro-
matic stability and/or the electron-poor nature of these
rings that easily undergo reduction under the conditions
required for the conversion of the nitrile to amine. An at-
tempt to increase the chemoselectivity (i.e., by lowering the
temperature to 0 °C) resulted in very low yields of the de-
sired amine.
Thus, for the synthesis of biaryls incorporating LiAlH4-
sensitive heterocycles, such as pyrimidine, thiazole, or pyr-
azole, a second version of the synthetic pathway was de-
signed that involved the introduction of a masked amino
group before the construction of the biaryl scaffold. In par-
ticular, the tert-butyloxycarbonyl group (Boc) was chosen
as the protecting group for the primary amine, due to its
stability under the basic conditions required for the cou-
pling and to the ease of removal (Scheme 2). Briefly, the
Boc-protected amine 19, synthesized in accordance with
the literature,19 was reacted with 2-iodophenol to obtain
the intermediate 20 that was quantitatively converted into
the corresponding pinacolboronate derivative 21, using the
optimized conditions reported for 10 (Table 1, entry 8). The
pinacolboronic ester 21 was reacted with the selected com-
mercially available bromo derivatives under the same con-
ditions as described for 11 to provide the biaryls 22–27. Fi-
nally, deprotection of 22–27 under acidic conditions afford-
ed the desired amines 28–33.
In summary, a versatile and efficient method for the
synthesis of heteroaryl ortho-phenoxyethylamines has
been described. This approach offers the opportunity to ob-
tain a large variety of biaryls incorporating five-membered
rings with one (thiophene, furan) or two (thiazole, pyra-
zole, imidazole) heteroatoms and six-membered (pyridine,
pyrimidine) heteroaromatic cycles starting from electron-
poor aryl halide or electron-rich arylboronic acids. To date,
a number of new compounds have been synthesized using
this procedure and currently they are under investigation in
a field as important as medicinal chemistry.
Reagents, solvents, and other chemicals were used as purchased
without further purification, unless otherwise specified. Air- or mois-
ture-sensitive reactants and solvents were employed in reactions car-
ried out under N2 atmosphere, unless otherwise noted. Flash column
chromatography purification (medium-pressure liquid chromatogra-
phy) was carried out using Merck silica gel 60 (230–400 mesh,
ASTM). The structures of all the isolated compounds were ensured by
NMR spectra and elemental analysis (C,H,N). NMR data (1H and 13C,
1D and 2D experiments) were obtained using a DPX 400 Avance spec-
trometer (Bruker). Chemical shifts are expressed in δ (ppm). 1H NMR
chemical shifts are relative to TMS as an internal standard. 13C NMR
chemical shifts are relative to internal TMS at δ = 0.0 or to the 13C sig-
nal of solvent: CDCl3 δ = 77.04, CD3OD δ = 49.8, DMSO-d6 δ = 39.5. 1H
NMR data are reported as follows: chemical shift, multiplicity (stan-
dard abbreviations), coupling constants, number of protons, and as-
signment. The elemental analysis was performed on a Carlo Erba
1106 Analyzer in the Microanalysis Laboratory of the Life Sciences
Department of the Università degli Studi di Modena e Reggio Emilia
and the results shown here are within ± 0.4% of the theoretical values.
Scheme 2  Reagents and conditions: i) K2CO3, KI, DMF, 160 °C, 4 h, 95%; ii) Et3N, pinacolborane, Pd(OAc)2, (2-biphenyl)dicyclohexylphosphine, 1,4-
dioxane, 100 °C, 2 h, 99%; iii) ArBr, Na2CO3, Pd(PPh3)4, toluene–EtOH (3:1, v/v), 90 °C, 8 h, 34% (22), 42% (23), 88% (24), 33% (25), 54% (25), 76% (27); 
iv) HCl, EtOH, 0 to 70 °C, 2  h, 82% (28), 72% (29), 77% (30), 78% (31), 83% (32), 99% (33).
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A round-bottomed flask was charged with o-iodophenol (2 g, 9.09
mmol), bromoacetonitrile (3.16 g, 26.0 mmol), K2CO3 (6.28 g, 45.0
mmol), and a catalytic amount of 18-crown-6. The reaction mixture
was suspended in anhydrous acetone (35 mL) and heated in ‘open-
vessel’ conditions under microwave irradiation at 55 °C, 150 W for 1
h. Then, the reaction mixture was cooled to r.t. and the solvent was
evaporated under reduced pressure. The crude product was purified
using flash column chromatography to provide the title compound as
a colorless oil; yield: 2.114 g (8.16 mmol, 89%).
IR (neat): 1493, 1238, 1098, 1031, 780 cm–1.
1H NMR (400 MHz, CDCl3): δ = 4.75 (s, 2 H, CH2), 6.80 (dt, J = 1.2, 7.7
Hz, 1 H, CH-4 Ar), 6.92 (dd, J = 1.2, 7.7 Hz, 1 H, CH-6 Ar), 7.30 (dt,
J = 1.5, 7.7 Hz, 1 H, CH-5 Ar), 7.75 (dd, J = 1.5, 7.7 Hz, 1 H, CH-3 Ar).
13C NMR (100 MHz, CDCl3): δ = 54.9 (CH2), 86.7 (C-2 Ar), 113.7 (C-6
Ar), 114 6 (CN), 125.2 (C-4 Ar), 129.8 (C-5 Ar), 140.2 (C-3 Ar), 155.5
(C-1 Ar).
Anal. Calcd for C8H6INO: C, 37.09; H, 2.33; N, 5.41. Found: C, 37.24; H,
2.46; N, 5.56.
2-[2-(4,4,5,5-Tetramethyl-1,3-dioxolan-2-yl)phenoxy]acetonitrile 
(10)
Pinacolborane (4.93 mL, 34.0 mmol) and Et3N (7.28 mL, 52.4 mmol)
were added to a solution of 9 (3.4 g, 13.1 mmol) in anhydrous 1,4-
dioxane (35 mL) under N2. The mixture was degassed, purged with N2
for 10 minutes, and Pd(OAc)2 (0.146 g, 0.65 mmol, 5 mol%) and (2-
biphenyl)dicyclohexylphosphine (0.92 g, 2.62 mmol, 20 mol%) were
added. The mixture was vigorously stirred at 100 °C under N2 for 90
min. Then, the reaction mixture was allowed to cool to r.t. and care-
fully quenched with sat. aq NH4Cl at 0 °C. The mixture was then ex-
tracted with CH2Cl2 and the combined organic layers were dried
(Na2SO4), filtered, and evaporated. The crude product was purified us-
ing flash column chromatography to give the title compound as a col-
orless oil; yield: 3.22 g (12.4 mmol, 95%).
IR (neat): 3290 (br), 1774, 1511, 1438, 1366, 1309, 1108 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.37 [s, 12 H, 2 × C(CH3)2], 4.79 (s, 2 H,
CH2), 7.01 (d, J = 7.5 Hz, 1 H, CH-6 Ar), 7.13 (t, J = 7.5 Hz, 1 H, CH-4 Ar),
7.46 (t, J = 7.5 Hz, 1 H, CH-5 Ar), 7.79 (d, J = 7.5 Hz, 1 H, CH-3 Ar).
13C NMR (100 MHz, CDCl3): δ = 24.8 [2 × C(CH3)2], 56.0 (CH2), 83.8 [2 ×
C(CH3)2], 114 9 (CN), 115.3 (C-6 Ar), 115.6 (C-2 Ar), 123.9 (C-4 Ar),
132.8 (C-5 Ar), 137.3 (C-3 Ar), 161.6 (C-1 Ar).
Anal. Calcd for C14H18BNO3: C, 64.90; H, 7.00; N, 5.41. Found: C, 65.11;
H, 7.06; N, 5.38.
Suzuki-Coupling Reactions of 9; General Procedure A
A 100 mL round-bottomed flask, equipped with a condenser and a
magnetic stir bar, was charged with o-iodophenoxyacetonitrile (9; 1
equiv), Na2CO3 (2 equiv), and toluene–EtOH mixture (20 mL, 3:1 v/v).
Thereafter, the corresponding commercially available arylboronic
acid (1.2 equiv) was added to the resulting suspension. The mixture
was degassed, purged with N2 for 15–20 min, and then Pd(PPh3)4 (10
mol%) was added. The reaction mixture was heated at 90 °C for 8 h
under stirring. The reaction mixture was allowed to cool to r.t., brine
(20 mL) was added, and the mixture stirred for 30 min. The organic
layer was then diluted with EtOAc, transferred to a separatory funnel,
washed with H2O and brine, dried (Na2SO4), filtered, and concentrat-
ed under reduced pressure. The resulting residue was purified on sili-
ca gel to provide the title compound as an oil.
2-[2-(Thiophen-2-yl)phenoxy]acetonitrile (11)
The title compound was obtained by following General Procedure A
from 9 (0.400 g, 1.54 mmol) and 2-thiophenylboronic acid (0.237 g,
1.85 mmol) as a dark oil; yield: 0.233 g (1.08 mmol, 70%).
IR (neat): 3392, 1662, 1554, 1401, 1368, 1345, 1121, 892, 840 cm–1.
1H NMR (400 MHz, CDCl3): δ = 4.72 (s, 2 H, CH2), 6.98–7.06 (m, 2 H,
CH-6 Ar, CH-4 Thio), 7.09 (dt, J = 1.2, 7.6 Hz, 1 H, CH-4 Ar), 7.24 (dt,
J = 1.6, 7.6 Hz, 1 H, CH-5 Ar), 7.29 (dd, J = 1.1, 5.1 Hz, 1 H, CH-3 Thio),
7.37 (dd, J = 1.1, 3.7 Hz, 1 H, CH-5 Thio), 7.58 (dd, J = 1.6, 7.6 Hz, 1 H,
CH-3 Ar).
13C NMR (100 MHz, CDCl3): δ = 54.8 (CH2), 114.4 (C-6 Ar), 114 9 (CN),
123.9 (C-4 Ar), 124.9 (C-2 Ar), 126.1 (C-3 Thio), 126.3 (C-5 Thio),
127.1 (C-4 Thio), 128.6 (C-5 Ar), 129.7 (C-3 Ar), 138.1 (C-1 Thio),
152.7 (C-1 Ar).
Anal. Calcd for C12H9NOS: C, 66.95; H, 4.21; N, 6.51. Found: C, 66.99;
H, 4.23; N, 6.67.
2-[2-(Furan-2-yl)phenoxy]acetonitrile (12)
The title compound was obtained by following General Procedure A
from 9 (0.250 g, 0.97 mmol) and 2-furanylboronic acid (0.431 g, 3.86
mmol) as a yellow oil; yield: 0.177 g (0.89 mmol, 93%).
IR (neat): 3396, 3100, 1666, 1554, 1352, 1107, 950, 811 cm–1.
1H NMR (400 MHz, CDCl3): δ = 4.85 (s, 2 H, CH2), 6.52 (dd, J = 1.7, 3.4
Hz, 1 H, CH-4 Fur), 6.90 (dd, J = 0.7, 3.4 Hz, 1 H, CH-3 Fur), 7.04 (dd,
J = 1.3, 7.7 Hz, 1 H, CH-6 Ar), 7.18 (dt, J = 1.3, 7.7 Hz, 1 H, CH-4 Ar),
7.29 (dt, J = 1.7, 7.7 Hz, 1 H, CH-5 Ar), 7.50 (dd, J = 0.7, 1.7 Hz, 1 H, CH-
5 Fur), 7.90 (dd, J = 1.7, 7.7 Hz, 1 H, CH-3 Ar).
13C NMR (100 MHz, CDCl3): δ = 54.9 (CH2), 109.8 (C-5 Fur), 111.8 (C-4
Fur), 114.5 (C-6 Ar), 114 8 (CN), 123.7 (C-4 Ar), 125.3 (C-2 Ar), 128.6
(C-5 Ar), 129.7 (C-3 Ar), 141.1 (C-3 Fur), 150.3 (C-1 Fur), 152.8 (C-1
Ar).
Anal. Calcd for C12H9NO2: C, 72.35; H, 4.55; N, 7.03. Found: C, 72.43;
H, 4.72; N, 7.15.
Suzuki-Coupling Reactions of Pinacolboronate Esters 10 and 21; 
General Procedure B
A 100 mL round-bottomed flask, equipped with a condenser and a
magnetic stir bar, was charged with the corresponding bromohet-
eroaryl (1 equiv), Na2CO3 (2 equiv) and toluene–EtOH (20 mL, 3:1
v/v). Thereafter, compound 10 or 21 (see below for the preparation of
21) (2.0 equiv) was added to the resulting suspension. The mixture
obtained was degassed, purged with N2 for 15–20 min, and then
Pd(PPh3)4 (10 mol%) was added. The reaction mixture was stirred and
heated at 90 °C for 8 h. The mixture was allowed to cool to r.t., brine
(20 mL) was added, and stirred for 30 min. The organic layer was then
diluted with EtOAc, transferred to a separatory funnel, washed with
H2O and brine, dried (Na2SO4), filtered, and concentrated under re-
duced pressure. The resulting residue was purified on silica gel to
provide the title compound as an oil.
2-[2-(Pyridin-2-yl)phenoxy]acetonitrile (13)
The title compound was obtained by following General Procedure B
from 2-bromopyridine (0.157 g, 0.99 mmol) and 10 (0.309 g, 1.98
mmol) as a colorless oil; yield: 0.141 g (0.67 mmol, 68%).
IR (neat): 3358, 3206, 1774, 1658, 1585, 1359, 1145, 854 cm–1.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2015, 47, A–J
FL. I. Manasieva et al. PaperSyn thesis1H NMR (400 MHz, CDCl3): δ = 4.75 (s, 2 H, CH2), 7.11 (dd, J = 0.9, 8.2
Hz, 1 H, CH-6 Ar), 7.16–7.29 (m, 2 H, CH-4 Ar, CH-5 Pyr), 7.43 (ddd,
J = 1.7, 7.4, 8.2 Hz, 1 H, CH-5 Ar), 7.51–7.82 (m, 3 H, CH-3 Ar, CH-3 and
CH-4 Pyr), 8.65–8.74 (m, 1 H, CH-6 Pyr).
13C NMR (100 MHz, CDCl3): δ = 54.9 (CH2), 114.5 (C-6 Ar), 114 8 (CN),
121.5 (C-4 Pyr), 123.7 (C-4 Ar), 124.8 (C-6 Pyr), 125.3 (C-2 Ar), 128.6
(C-5 Ar), 129.7 (C-3 Ar), 135.3 (C-5 Pyr) 149.6 (C-3 Pyr), 152.6 (C-1
Ar) 157.6 (C-1 Pyr).
Anal. Calcd for C13H10N2O: C, 74.27; H, 4.79; N, 13.33. Found: C, 74.31;
H, 4.88; N, 13.22.
2-[2-(Pyridin-3-yl)phenoxy]acetonitrile (14)
The title compound was obtained by following General Procedure B
from 3-bromopyridine (0.093 mL, 0.96 mmol) and 10 (0.30 g, 1.16
mmol) as a colorless oil; yield: 0.096 g (0.45 mmol, 40%).
IR (neat): 3375, 1663, 1637, 1559, 1394, 1349, 1127, 876, 808 cm–1.
1H NMR (400 MHz, CDCl3): δ = 4.71 (s, 2 H, CH2), 7.12 (dd, J = 0.9, 8.2
Hz, 1 H, CH-6 Ar), 7.21 (dt, J = 0.9, 8.6 Hz, 1 H, CH-4 Ar), 7.30–7.52 (m,
3 H, CH-5 Pyr, CH-3 and CH-5 Ar), 7.81 (dt, J = 1.8, 7.9 Hz, 1 H, CH-4
Ar), 8.59 (d, J = 1.8, 4.9 Hz, 1 H, CH-6 Pyr), 8.72 (dd, J = 0.8, 2.3 Hz, 1 H,
CH-2 Pyr).
13C NMR (100 MHz, CDCl3): δ = 54.9 (CH2), 114.5 (C-6 Ar), 114 8 (CN),
122.8 (C-5 Pyr), 123.7 (C-4 Ar), 125.3 (C-2 Ar), 128.6 (C-5 Ar), 129.7
(C-3 Ar), 134.6 (C-1 Pyr), 136.9 (C-6 Pyr) 148.2 (C-4 Pyr), 150.2 (C-2
Pyr), 152.6 (C-1 Ar).
Anal. Calcd for C13H10N2O: C, 74.27; H, 4.79; N, 13.33. Found: C, 74.43;
H, 4.92; N, 13.39.
LiAlH4 Reduction of Nitriles; General Procedure C
The selected nitrile derivative (1 equiv) was dissolved in of anhydrous
Et2O (1–9 mL) and added dropwise to a suspension of LiAlH4 (3 equiv)
in anhydrous Et2O (2 mL) at 0 °C. The excess of the reducing agent was
immediately and carefully quenched with H2O and 5% aq NaOH. The
reaction mixture was stirred for 15 min and then EtOAc was added.
The resulting organic phase was washed with brine, dried (Na2SO4),
filtered, and evaporated under reduced pressure. The crude product
was used in the next synthetic step without any purification.
2-[2-(Thiophen-2-yl)phenoxy]ethanamine (15)
The title compound was obtained by following General Procedure C
from 11 (0.223 g, 1.03 mmol) as a colorless oil; yield: 0.208 g (0.94
mmol, 92%).
IR (neat): 3425 (br), 3248, 3085, 1859, 1641, 1388, 1365, 1101, 813,
708 cm–1.
1H NMR (400 MHz, CDCl3): δ = 2.76 (br s, 2 H, NH2), 3.16 (t, J = 5.0 Hz,
2 H, CH2NH2), 4.08 (t, J = 5.0 Hz, 2 H, OCH2), 6.95 (dd, J = 1.0, 8.2 Hz, 1
H, CH-6 Ar), 7.02 (dt, J = 1.0, 7.6 Hz, 1 H, CH-4 Ar), 7.11 (dd, J = 3.7, 5.1
Hz, 1 H, CH-4 Thio), 7.23–7.30 (m, 1 H, CH-5 Ar), 7.35 (dd, J = 1.1, 5.1
Hz, 1 H, CH-5 Thio), 7.50 (dd, J = 1.1, 3.7 Hz, 1 H, CH-3 Thio), 7.69 (dd,
1 H, J = 1.7, 7.6 Hz, CH-3 Ar).
13C NMR (100 MHz, CDCl3): δ = 47.4 (CH2NH2), 70.6 (OCH2), 112.5 (C-6
Ar), 121.3 (C-4 Ar), 123.2 (C-2 Ar), 124.9 (C-3 Thio), 125.5 (C-5 Thio),
126.7 (C-4 Thio), 128.4 (C-5 Ar), 128.7 (C-3 Ar), 139.2 (C-1 Thio),
154.6 (C-1).
Anal. Calcd for C12H13NOS: C, 65.72; H, 5.97; N, 6.39. Found: C, 65.83;
H, 6.16; N, 6.67.
2-[2-(Furan-2-yl)phenoxy]ethanamine (16)
The title compound was obtained by following General Procedure C
from 12 (0.170 g, 0.85 mmol) as a yellow oil; yield: 0.103 g (0.50
mmol, 60%).
IR (neat): 3368 (br), 3251, 3146, 1859, 1667, 1354, 1093, 863, 706 cm–
1.
1H NMR (400 MHz, CDCl3): δ = 1.40 (br s, 2 H, NH2), 3.20 (t, J = 5.1 Hz,
2 H, CH2NH2), 4.14 (t, J = 5.1 Hz, 2 H, OCH2), 6.50 (dd, J = 1.7, 3.2 Hz, 1
H, CH-4 Fur), 6.94 (dd, J = 0.7, 3.2 Hz, 1 H, CH-3 Fur), 6.96 (dd, J = 1.2,
8.0 Hz, 1 H, CH-6 Ar), 7.04 (dt, J = 1.2, 7.6 Hz, 1 H, CH-4 Ar), 7.24 (ddd,
J = 1.7, 7.6, 8.0 Hz, 1 H, CH-5 Ar), 7.48 (dd, J = 0.7, 1.7 Hz, 1 H, CH-5
Fur), 7.87 (dd, J = 1.7, 7.6 Hz, 1 H, CH-3 Ar).
13C NMR (100 MHz, CDCl3): δ = 47.6 (CH2NH2), 70.7 (OCH2),109.9 (C-5
Fur), 111.8 (C-4 Fur), 112.7 (C-6 Ar), 120.3 (C-2 Ar), 121.2 (C-4 Ar),
128.4 (C-5 Ar), 128.6 (C-3 Ar), 141.3 (C-3 Fur), 150.4 (C-1 Fur), 154.6
(C-1).
Anal. Calcd for C12H13NO2: C, 70.92; H, 6.45; N, 6.89. Found: C, 70.96;
H, 6.53; N, 6.95.
2-[2-(Pyridin-2-yl)phenoxy]ethanamine (17)
The title compound was obtained by following General Procedure C
from 13 (0.215 g, 1.02 mmol) as a yellow oil; yield: 0.195 g (0.91
mmol, 79%).
IR (neat): 3374 (br), 3236, 3171, 3101, 1853, 1781, 1625, 1390, 1153,
652 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.60 (br s, 2 H, NH2), 3.03 (t, J = 5.2 Hz,
2 H, CH2NH2), 4.05 (t, J = 5.2 Hz, 2 H, OCH2), 7.02 (dd, J = 1.0, 8.4 Hz, 1
H, CH-6 Ar), 7.10 (dt, J = 1.0, 7.6 Hz, 1 H, CH-4 Ar), 7.16–7.25 (m, 1 H,
CH-5 Pyr), 7.31–7.40 (m, 1 H, CH-5 Ar), 7.62–7.83 (m, 3 H, CH-3 Ar,
CH-3 and CH-4 Pyr), 8.63 (d, J = 4.6 Hz, 1 H, CH-6 Pyr).
13C NMR (100 MHz, CDCl3): δ = 52.2 (CH2NH2), 68.9 (OCH2), 113.1 (C-6
Ar), 121.6 (C-4 Pyr), 121.9 (C-4 Ar), 124.9 (C-6 Pyr), 128.1 (C-2 Ar),
128.7 (C-5 Ar), 129.7 (C-3 Ar), 135.3 (C-5 Pyr) 149.3 (C-3 Pyr), 152.6
(C-1 Ar), 155.9 (C-1 Pyr).
Anal. Calcd for C13H14N2O: C, 72.87; H, 6.59; N, 13.07. Found: C, 72.85;
H, 6.69; N, 13.21.
2-[2-(Pyridin-3-yl)phenoxy]ethanamine (18)
The title compound was obtained by following General Procedure C
from 14 (0.199 g, 0.95 mmol) as a yellow oil; yield: 0.180 g (0.84
mmol, 79%).
IR (neat): 3372 (br), 3247, 3150, 1857, 1663, 1396, 1356, 1129, 711
cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.79 (br s, 2 H, NH2), 2.95 (t, J = 5.2 Hz,
2 H, CH2NH2), 3.93 (t, J = 5.2 Hz, 2 H, OCH2), 6.93–7.06 (m, 2 H, CH-4,
CH-6 Ar), 7.19–7.32 (m, 3 H, CH-5 Pyr, CH-3 and CH-5 Ar), 7.81 (dt,
J = 1.8, 7.9 Hz, 1 H, CH-4 Pyr), 8.51 (dd, J = 1.8, 4.9 Hz, 1 H, CH-6 Pyr),
8.75 (dd, J = 0.9, 2.4 Hz, 1 H, CH-2 Pyr).
13C NMR (100 MHz, CDCl3): δ = 52.3 (CH2NH2), 68.7 (OCH2), 113.3 (C-6
Ar), 121.9 (C-4 Ar), 122.6 (C-5 Pyr), 128.1 (C-2 Ar), 128.7 (C-5 Ar),
129.7 (C-3 Ar), 134.3 (C-1 Pyr), 136.8 (C-6 Pyr) 148.1 (C-4 Pyr), 150.1
(C-2 Pyr), 152.6 (C-1 Ar).
Anal. Calcd for C13H14N2O: C, 72.87; H, 6.59; N, 13.07. Found: C, 72.96;
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In a round-bottomed flask, 2-chloroethylamine hydrochloride (2 g,
17.0 mmol) and Et3N (2.37 mL, 11.0 mmol) were dissolved in anhy-
drous CH2Cl2 (24 mL). Boc2O (3.6 mL, 15.3 mmol) was added to the
resulting solution under N2 at 0 °C. The reaction mixture was stirred
at r.t. for 4 h. The mixture was then washed with H2O and brine, dried
(Na2SO4), filtered, and concentrated under reduced pressure to give
the title product as a dark liquid; yield: 2.91 g (16.21 mmol, 99%),
which was used directly in the next synthetic step.
IR (neat): 3347, 2924, 2854, 2361, 2342, 1725, 1709, 1503, 1462 cm–1.
1H NMR (400 MHz, CDCl3): δ = ?? [s, 9 H, C(CH3)3], 3.36–3.48 (m, 2 H,
CH2NH), 3.49–3.63 (m, 2 H, ClCH2), 4.93 (br s, 1 H, NHCO).
13C NMR (100 MHz, CDCl3): δ = 28.2 [C(CH3)3], 32.8 (CH2NH), 45.7
(CH2Cl), 79.8 [C(CH3)3], 155.8 (C=O).
Anal. Calcd for C7H14ClNO2: C, 46.80; H, 7.86; N, 7.80. Found: C, 46.91;
H, 7.89; N, 7.74.
tert-Butyl [2-(2-Iodophenoxy)ethyl]carbamate (20)
Compound 19 (4.9 g, 27.27 mmol) and KI (7.55 g, 45.46 mmol) were
added to a solution of o-iodophenol (5.0 g, 22.73 mmol) in anhydrous
DMF (80 mL) in the presence of K2CO3 (9.43 g, 68.2 mmol). The reac-
tion mixture was magnetically stirred and refluxed for 4 h. Then the
reaction mixture was cooled to r.t. and the solvent was evaporated
under reduced pressure. The resulting residue was dissolved in EtOAc,
and the EtOAc layer was washed with H2O and brine, dried (Na2SO4),
filtered, and concentrated under reduced pressure to afford the title
compound as a dark oil; yield: 8.34 g (22.97 mmol, 98%).
IR (neat): 3268, 1858, 1672, 1641, 1385, 1347, 1138, 1075 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.45 [s, 9 H, C(CH3)3], 3.59 (q, 2 H,
J = 5.3 Hz, CH2NH), 4.06 (t, J = 4.9 Hz, 2 H, OCH2), 6.13 (br s, 1 H, NH),
6.73 (dt, J = 1.5, 7.6 Hz, 1 H, CH-4 Ar), 6.81 (dd, J = 1.5, 8.2 Hz, 1 H, CH-
6 Ar), 7.29 (ddd, J = 1.5, 7.6, 8.2 Hz, 1 H, CH-5 Ar), 7.77 (dd, J = 1.5, 7.8
Hz, 1 H, CH-3 Ar).
13C NMR (100 MHz, CDCl3): δ = 28.2 [C(CH3)3], 39.8 (CH2NH), 68.4
(OCH2), 79.2 [C(CH3)3], 86.6 (C-2 Ar), 112.3 (C-6 Ar), 122.8 (C-4 Ar),
129.4 (C-5 Ar), 139.1 (C-3 Ar), 155.7 (C-1 Ar), 156.8 (NHCO2).
Anal. Calcd for C13H18INO3: C, 42.99; H, 5.00; N, 3.86. Found: C, 43.23;
H, 5.18; N, 3.96.
tert-Butyl {2-[2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborlan-2-yl)phe-
noxy]ethyl}carbamate (21)
Pinacolborane (0.387 mL, 2.66 mmol) and Et3N (0.574 mL, 4.12
mmol) were added to a solution of 20 (0.372 g, 1.03 mmol) in anhy-
drous 1,4-dioxane (10 mL) under N2. The mixture was degassed,
purged with N2 for 10 min, and Pd(OAc)2 (0.015 g, 0.05 mmol, 5 mol%)
and (2-biphenyl)dicyclohexylphosphine (0.098 g, 0.2 mmol, 20 mol%)
were added. The mixture was vigorously stirred at 100 °C under N2
for 2 h. The reaction mixture was allowed to cool to r.t., carefully
quenched with sat. aq NH4Cl at 0 °C, and extracted with CH2Cl2. The
combined organic layers were dried (Na2SO4), filtered, and evaporat-
ed under reduced pressure. The crude product was purified by flash
column chromatography to give the title compound as a yellow oil;
yield: 0.216 g (0.59 mmol, 99%).
IR (neat): 3295 (br), 3200, 1836, 1710, 1503, 1345, 841 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.39 [s, 9 H, C(CH3)3], 1.47 [s, 12 H, 2 ×
C(CH3)2], 3.59 (q, J = 5.1 Hz, 2 H, CH2NH), 4.06 (t, J = 5.1 Hz, 2 H, OCH2),
6.18 (br s, 1 H, NH), 6.85 (d, J = 8.3 Hz, 1 H, CH-6 Ar), 6.98 (dt, J = 0.9,
7.4 Hz, 1 H, CH-4 Ar), 7.43 (ddd, J = 1.8, 7.4, 8.3 Hz, 1 H, CH-5 Ar), 7.71
(dd, J = 1.8, 7.4 Hz, 1 H, CH-3 Ar).
13C NMR (100 MHz, CDCl3): δ = 24.9 [2 × C(CH3)2], 28.4 [C(CH3)3], 39.9
(CH2NH), 68.3 (OCH2), 79.4 [C(CH3)3], 83.6 [2 × C(CH3)2], 114.9 (C-6
Ar), 115.7 (C-2 Ar), 123.2 (C-4 Ar), 131.8 (C-5 Ar), 138.2 (C-3 Ar),
156.7 (NHCO2), 160.9 (C-1 Ar).
Anal. Calcd for C19H30BNO5: C, 62.82; H, 8.32; N, 3.86. Found: C, 63.02;
H, 8.41; N, 3.71.
tert-Butyl N-{2-[2-(Pyrimidin-2-yl)phenoxy]ethyl}carbamate (22)
The title compound was obtained by following General Procedure B
from 2-bromopyrimidine (0.238 g, 1.5 mmol) and 21 (0.694 g, 1.90
mmol) as a dark oil; yield: 0.171 g, 0.54 mmol (34%).
IR (neat): 3279, 1854, 1740, 1520, 1441, 1375, 1024 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.36 [s, 9 H, C(CH3)3], 3.51 (t, J = 4.9 Hz,
2 H, CH2NH), 4.25 (t, J = 4.9 Hz, 2 H, CH2O), 5.29 (br s, 1 H, NH), 7.06 (d,
J = 8.3 Hz, 1 H, CH-6 Ar), 7.08–7.13 (m, 1 H, CH-4 Ar), 7.25 (t, J = 4.9
Hz, 1 H, CH-5 Pyrim), 7.39–7.48 (m, 1 H, CH-5 Ar), 7.82–7.91 (m, 1 H,
CH-3 Ar), 8.92 (d, J = 4.9 Hz, 2 H, CH-4, CH-6 Pyrim).
13C NMR (100 MHz, CDCl3): δ = 28.3 [C(CH3)3], 40.2 (CH2NH), 68.1
(OCH2), 79.7 [C(CH3)3], 112.3 (C-6 Ar), 118.7 (C-5 Pyrim), 121.5 (C-4
Ar), 128.1 (C-2 Ar), 129.6 (C-5 Ar), 131.3 (C-3 Ar), 154.4 (C-1 Ar),
156.9 (C-4, C-6 Pyrim), 155.9 (C=O), 165.96 (C-2 Pyrim).
Anal. Calcd for C17H21N3O3: C, 64.74; H, 6.71; N, 13.32. Found: C,
64.62; H, 6.41; N, 13.61.
tert-Butyl N-{2-[2-(Pyrimidin-5-yl)phenoxy]ethyl}carbamate (23)
The title compound was obtained by following General Procedure B
from 5-bromopyrimidine (0.238 g, 1.5 mmol) and 21 (0.694 g, 1.90
mmol) as a dark oil; yield: 0.206 g (0.65 mmol, 42%).
IR (neat): 3277 (br), 1847, 1670, 1552, 1343, 883, 686 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.42 [s, 9 H, C(CH3)3], 3.46 (t, J = 5.4 Hz,
2 H, CH2NH), 4.09 (t, J = 5.2 Hz, 2 H, OCH2), 4.72 (br s, 1 H, NH), 7.04
(dd, J = 1.2, 8.3 Hz, CH-6 Ar), 7.12 (td, J = 1.2, 7.4 Hz, 1 H, CH-4 Ar),
7.35 (dd, J = 1.8, 7.4 Hz, 1 H, CH-3 Ar), 7.42 (ddd, J = 1.8, 7.4, 8.3 Hz, 1
H, CH-5 Ar), 8.89 (s, 2 H, CH-4, CH-6 Pyrim), 9.17 (s, 1 H, CH-2 Pyrim).
13C NMR (100 MHz, CDCl3): δ = 28.3 [C(CH3)3], 40.2 (CH2NH), 68.3
(OCH2), 79.9 [C(CH3)3], 112.3 (C-6 Ar), 121.5 (C-4 Ar), 124.4 (C-3 Ar),
130.2 (C-2 Ar), 130.6 (C-5 Ar), 132.2 (C-5 Pyrim), 154.4 (C-1 Ar), 155.9
(C=O), 156.5 (C-4, C-6 Pyrim), 156.8 (C-2 Pyrim).
Anal. Calcd for C17H21N3O3: C, 64.74; H, 6.71; N, 13.32. Found: C,
64.60; H, 6.49; N, 13.56.
tert-Butyl N-{2-[2-(1,3-Thiazol-2-yl)phenoxy]ethyl}carbamate 
(24)
The title compound was obtained by following General Procedure B
from 2-bromothiazole (0.060 g, 0.34 mmol) and 21 (0.174 g, 0.48
mmol) as a dark oil; yield: 0.095 g (0.30 mmol, 88%).
IR (neat): 3291, 3200, 1830, 1716, 1438, 1352, 1052, 876 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.43 [s, 9 H, C(CH3)3], 3.73 (t, J = 5.2 Hz,
2 H, CH2NH), 4.27 (t, J = 5.2 Hz, 2 H, OCH2), 5.25 (br s, 1 H, NH), 7.02
(dd, J = 1.0, 8.3 Hz, 1 H, CH-6 Ar), 7.12 (dt, J = 1.0, 7.9 Hz, 1 H, CH-4
Ar), 7.40 (ddd, J = 1.8, 7.9, 8.3 Hz, 1  H, CH-5 Ar), 7.42 (d, J = 3.4 Hz, 1
H, CH-5 Thia), 7.94 (d, J = 3.4 Hz, 1 H, CH-4 Thia), 8.40 (dd, J = 1.8, 7.9
Hz, 1 H, CH-3 Ar).
13C NMR (100 MHz, CDCl3): δ = 28.6 [C(CH3)3], 40.3 (CH2NH), 68.2
(OCH2), 79.7 [C(CH3)3], 112.1 (C-6 Ar), 119.5 (C-5 Thia), 121.4 (C-4 Ar),
122.1 (C-2 Ar), 128.7 (C-3 Ar), 130.9 (C-5 Ar), 142.1 (C-4 Thia), 155.5
(C-1 Ar), 155.9 (C=O), 162.1 (C-2 Thia).© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2015, 47, A–J
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60.12; H, 6.37; N, 8.91.
tert-Butyl N-{2-[2-(1,3-Thiazol-5-yl)phenoxy]ethyl}carbamate 
(25)
The title compound was obtained by following the General Procedure
B from 5-bromothiazole (0.087 g, 0.64 mmol) and 21 (0.192 g, 0.53
mmol) as a dark oil; yield: 0.057 g (0.18 mmol, 33%).
IR (neat): 3291, 1832, 1708, 1467, 1395, 1338, 880 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.49 [s, 9 H, C(CH3)3], 3.60–3.74 (m, 2
H, CH2NH), 4.20 (t, J = 5.0 Hz, 2 H, OCH2), 5.04 (br s, 1 H, NH), 7.02 (d,
J = 8.3 Hz, 1 H, CH-6 Ar), 7.09 (dt, J = 1.0, 7.6 Hz, 1 H, CH-4 Ar), 7.36
(ddd, J = 1.5, 7.6, 8.3 Hz, 1 H, CH-5 Ar), 7.71 (dd, J = 1.5, 7.6 Hz, 1 H,
CH-3 Ar), 8.29 (s, 1 H, CH-4 Thia), 8.85 (s, 1 H, CH-2 Thia).
13C NMR (100 MHz, CDCl3): δ = 28.4 [C(CH3)3], 40.1 (CH2NH), 68.1
(OCH2), 79.8 [C(CH3)3], 112.3 (C-6 Ar), 120.2 (C-2 Ar), 121.5 (C-4 Ar),
128.8 (C-3 Ar), 129.6 (C-5 Ar), 133.8 (C-5 Thia), 140.9 (C-4 Thia),
152.9 (C-2 Thia), 154.4 (C-1 Ar), 155.9 (C=O).
Anal. Calcd for C16H20N2O3S: C, 59.98; H, 6.29; N, 8.74. Found: C,
59.82; H, 6.39; N, 8.89.
tert-Butyl N-{2-[2-(1-Methyl-1H-pyrazol-4-yl)phenoxy]ethyl}car-
bamate (26)
The title compound was obtained by following the General Procedure
B from 4-bromo-1-methyl-1H-pyrazole (0.084 g, 0.52 mmol) and 21
(0.190 g, 0.52 mmol) as a dark oil; yield: 0.090 g (0.28 mmol, 54%).
IR (neat): 3291 (br), 1809, 1708, 1442, 1385, 893 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.49 [s, 9 H, C(CH3)3], 3.60–3.75 (m, 2
H, CH2NH), 4.00 (s, 3 H, NCH3), 4.16 (t, J = 5.2 Hz, 2 H, OCH2), 4.90 (br
s, 1 H, NH), 6.96 (d, J = 7.6 Hz, 1 H, CH-6 Ar), 7.04 (dt, J = 0.9, 7.5 Hz, 1
H, CH-4 Ar), 7.17–7.26 (m, 1 H, CH-5 Ar), 7.56 (dd, J = 1.6, 7.6 Hz, 1 H,
CH-3 Ar), 7.89 (s, 1 H, CH-5 Pyra), 7.90 (s, 1 H, CH-3 Pyra).
13C NMR (100 MHz, CDCl3): δ = 28.4 [C(CH3)3], 39.0 (NCH3), 40.3
(CH2NH), 67.6 (OCH2), 79.6 [C(CH3)3], 112.4 (C-6 Ar), 118.5 (C-4 Pyra),
121.4 (C-4 Ar), 121.8 (C-2 Ar), 127.3 (C-5 Ar), 127.9 (C-3 Ar), 129.4 (C-
5 Pyra), 138.1 (C-3 Pyra), 154.7 (C-1 Ar), 155.9 (C=O).
Anal. Calcd for C17H23N3O3: C, 64.33; H, 7.30; N, 13.24. Found: C,
64.26; H, 7.21; N, 13.39.
tert-Butyl N-{2-[2-(1-Methyl-1H-imidazol-5-yl)phenoxy]eth-
yl}carbamate (27)
The title compound was obtained by following the General Procedure
B from 5-bromo-1-methyl-1H-imidazole (0.391 g, 2.44 mmol) and 21
(0.444 g, 1.22 mmol) as an oil; yield: 0.294 g (0.93 mmol, 76%).
IR (neat): 3215 (br), 1833, 1707, 1445, 1338, 1123 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.42 [s, 9 H, C(CH3)3], 3.40 (m, 2 H,
CH2NH), 3.51 (s, 3 H, NCH3), 4.03 (t, J = 5.2 Hz, 2 H, OCH2), 4.84 (br s, 1
H, NH), 6.90–7.06 (m, 3 H, CH-4 and CH-6 Ar, CH-4 Imi), 7.21–7.31 (m,
1 H, CH-5 Ar), 7.33–7.42 (m, 1 H, CH-3 Ar), 7.50 (s, 1 H, CH-2 Imi).
13C NMR (100 MHz, CDCl3): δ = 28.5 [C(CH3)3], 32.4 (NCH3), 40.4
(CH2NH), 67.8 (OCH2), 79.7 [C(CH3)3], 112.3 (C-6 Ar), 121.5 (C-4 Ar),
121.7 (C-2 Ar), 127.3 (C-5 Ar), 127.9 (C-3 Ar), 128.6 (C-4 Imi), 129.9
(C-5 Imi),138.5 (C-2 Imi), 154.7 (C-1 Ar), 155.9 (C=O).
Anal. Calcd for C17H23N3O3: C, 64.33; H, 7.30; N, 13.24. Found: C,
64.45; H, 7.51; N, 13.46.
Hydrolysis of Boc Esters; General Procedure D
A 25 mL round-bottomed flask was charged with the selected NHBoc
derivative (1 equiv) and EtOH (5 mL). The solution was cooled to 0 °C
in an ice water bath and 1.25 M HCl in EtOH (15 equiv) solution was
added dropwise. The reaction was allowed to warm to r.t. and re-
fluxed for 2 h. The reaction was monitored by TLC (eluent: ????). The
resulting suspension was cooled to r.t. and the solvent was removed
under reduced pressure. The crude solid product was dissolved in
H2O and then aq 5% NaOH was added until pH 12. The resulting solu-
tion was extracted with CH2Cl2. The combined organic layers were
dried (Na2SO4), filtered, and concentrated under reduced pressure to
afford the corresponding pure product.
2-[2-(Pyrimidin-2-yl)phenoxy]ethanamine (28)
The title compound was obtained by following General Procedure D
from 22 (0.171 g, 0.54 mmol) as a dark oil; yield: 0.092 g (0.42 mmol,
82%).
IR (neat): 3380, 1733, 1709, 1596, 1401, 1397, 985, 907, 715 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.79 (br s, 2 H), 3.00 (t, J = 4.8 Hz, 2 H,
CH2NH2), 4.07 (t, J = 4.8 Hz, 2 H, OCH2), 7.04 (d, J = 8.3 Hz, 1 H, CH-6
Ar), 7.09 (td, J = 0.9, 7.5 Hz, 1 H, CH-4 Ar), 7.22 (t, J = 4.9 Hz, 1 H, CH-5
Pyrim), 7.42 (ddd, J = 1.8, 7.5, 8.3 Hz, 1 H, CH-5 Ar), 7.79 (dd, J = 1.8
7.5 Hz, 1 H, CH-3 Ar), 8.85 (d, J = 4.9 Hz, 2 H, CH-4, CH-6 Pyrim).
13C NMR (100 MHz, CDCl3): δ = 41.6 (CH2NH2), 71.3 (OCH2), 113.7 (C-6
Ar), 118.7 (C-5 Pyrim), 121.1 (C-4 Ar), 128.6 (C-2 Ar), 131.1 (C-5 Ar),
131.7 (C-3 Ar), 156.9 (C-4, C-6 Pyrim), 157.1 (C-1 Ar), 165.96 (C-2 Py-
rim).
Anal. Calcd for C12H13N3O: C, 66.96; H, 6.09; N, 19.52. Found: C, 66.90;
H, 6.00; N, 19.66.
2-[2-(Pyrimidin-5-yl)phenoxy]ethanamine (29)
The title compound was obtained by following General Procedure D
from 23 (0.181 g, 0.57 mmol) as a dark oil; yield: 0.089 g (0.41 mmol,
72%).
IR (neat): 3248, 3166, 1677, 1563, 1405, 1387, 899, 818 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.50 (br s, 2 H, NH2), 3.05 (t, J = 5.3 Hz,
2 H, CH2NH2), 4.04 (t, J = 5.3 Hz, 2 H, OCH2), 7.05 (dd, J = 0.9, 8.3 Hz, 1
H, CH-6 Ar), 7.11 (td, J = 0.9, 7.5 Hz, 1 H, CH-4 Ar), 7.35 (dd, J = 1.8, 7.5
Hz, 1 H, CH-3 Ar), 7.42 (ddd, J = 1.8, 7.5, 8.3 Hz, 1 H, CH-5 Ar), 8.93 (s,
2 H, CH-4, CH-6 Pyrim), 9.17 (s, 1 H, CH-2 Pyrim).
13C NMR (100 MHz, CDCl3): δ = 41.4 (CH2NH2), 70.8 (OCH2), 112.5 (C-6
Ar), 121.6 (C-4 Ar), 123.6 (C-3 Ar), 130.4 (C-3 Ar), 130.6 (C-5 Ar),
132.2 (C-5 Pyrim), 155.9 (C-1 Ar), 156.8 (C-4, C-6 Pyrim), 156.9 (C-2
Pyrim).
Anal. Calcd for C12H13N3O: C, 66.96; H, 6.09; N, 19.52. Found: C, 66.92;
H, 6.07; N, 19.59.
2-[2-(Thiazol-2-yl)phenoxy]ethanamine (30)
The title compound was obtained by following General Procedure D
from 24 (0.135 g, 0.42 mmol) as a dark oil; yield: 0.072 g (0.33 mmol,
77%).
IR (neat): 3399 (br), 3233, 1665, 1397, 1099, 1063, 886, 629 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.73 (br s, 2 H, NH2), 3.32 (t, J = 5.1 Hz,
2 H, CH2NH2), 4.28 (t, J = 5.1 Hz, 2 H, OCH2), 7.07 (d, J = 7.9 Hz, 1 H,
CH-6 Ar), 7.14 (dt, J = 1.0, 7.8 Hz, 1 H, CH-4 Ar), 7.38–7.50 (m, 2 H, CH-
5 Thia, CH-5 Ar), 7.97 (d, J = 3.6 Hz, 1 H, CH-4 Thia), 8.45 (dd, J = 1.6,
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Ar), 119.5 (C-5 Thia), 121.2 (C-4 Ar), 122.2 (C-2 Ar), 128.6 (C-3 Ar),
130.7 (C-5 Ar), 141.9 (C-4 Thia), 155.4 (C-1 Ar), 162.3 (C-2 Thia).
Anal. Calcd for C11H12N2OS: C, 59.97; H, 5.49; N, 12.72. Found: C,
60.13; H, 5.66; N, 12.98.
2-[2-(Thiazol-5-yl)phenoxy]ethanamine (31)
The title compound was obtained by following General Procedure D
from 25 (0.056 g, 0.17 mmol) as a dark oil; yield: 0.030 g (0.14 mmol,
78%).
IR (neat): 3283, 3208, 1843, 1666, 1395, 1129, 888, 874 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.58 (br s, 2 H, NH2), 3.20 (t, J = 5.2 Hz,
2 H, CH2NH2), 4.14 (t, J = 5.2 Hz, 2 H, CH2O), 7.00 (d, J = 8.3 Hz, 1 H,
CH-6 Ar), 7.04 (dt, J = 1.0, 7.5 Hz, 1 H, CH-4 Ar), 7.27–7.36 (m, 1 H, CH-
5 Ar), 7.67 (dd, J = 1.6, 7.5 Hz, 1 H, CH-3 Ar), 8.27 (s, 1 H, CH-4 Thia),
8.79 (s, 1 H, CH-2 Thia).
13C NMR (100 MHz, CDCl3): δ = 41.7 (CH2NH2), 71.5 (OCH2), 112.0 (C-6
Ar), 121.2 (C-4 Ar), 122.2 (C-2 Ar), 128.6 (C-3 Ar), 130.7 (C-5 Ar),
133.7 (C-5 Thia), 141.1 (C-4 Thia), 153.0 (C-2 Thia), 155.4 (C-1 Ar).
Anal. Calcd for C11H12N2OS: C, 59.97; H, 5.49; N, 12.72. Found: C,
60.13; H, 5.66; N, 12.98.
2-[2-(1-Methyl-1H-pyrazol-4-yl)phenoxy]ethanamine (32)
The title compound was obtained by following General Procedure D
from 26 (0.117 g, 0.34 mmol) as a dark oil; yield: 0.067 g (0.31 mmol,
83%).
IR (neat): 3302, 3278, 1782, 1691, 1580, 1385, 113, 858 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.55 (br s, 2 H, NH2), 3.17 (t, J = 4.9 Hz,
2 H, CH2NH2), 3.95 (s, 3 H, NCH3), 4.10 (t, J = 4.9 Hz, 2 H, OCH2), 6.86
(d, J = 8.1 Hz, 1 H, CH-6 Ar), 6.94 (dt, J = 1.2, 7.6 Hz, 1 H, CH-4 Ar),
7.18–7.27 (m, 1 H, CH-5 Ar), 7.51 (d, J = 7.6 Hz, 1 H, CH-3 Ar), 7.76–
7.90 (m, 2 H, CH-4, CH-5 Pyra).
13C NMR (100 MHz, CDCl3): δ = 39.1 (NCH3), 39.7 (NH2CH2), 67.4
(CH2O), 112.6 (C-6 Ar), 117.9 (C-4 Pyra), 121.7 (C-2 Ar), 121.7 (C-4
Ar), 127.8 (C-5 Ar), 128.6 (C-3 Ar), 130.1 (C-5 Pyra), 137.0 (C-3 Pyra),
155.2 (C-1 Ar).
Anal. Calcd for C12H15N3O: C, 66.34; H, 6.96; N, 19.34. Found: C, 66.46;
H, 7.17; N, 19.44.
2-[2-(1-Methyl-1H-imidazol-5-yl)phenoxy]ethanamine (33)
The title compound was obtained by following General Procedure D
from 27 (0.294 g, 0.93 mmol) as a dark oil; yield: 0.202 g (0.92 mmol,
99%).
IR (neat): 3281, 3225, 3045, 1845, 1684, 1394, 1137, 886, 603 cm–1.
1H NMR (400 MHz, CDCl3): δ = 1.37 (br s, 2 H, NH2), 2.98 (t, J = 5.3 Hz,
2 H, CH2NH2), 3.55 (s, 3 H, NCH3), 4.00 (t, J = 5.3 Hz, 2 H, OCH2), 6.95–
7.18 (m, 3 H, CH-4 and CH-6 Ar, CH-4 Imi), 7.21–7.32 (m, 1 H, CH-5
Ar), 7.37–7.47 (m, 1 H, CH-3 Ar), 7.53 (s, 1 H, CH-2 Imi).
13C NMR (100 MHz, CDCl3): δ = 32.2 (NCH3), 41.4 (NH2CH2), 70.9
(CH2O), 112.7 (C-6 Ar), 119.4 (C-2 Ar), 121.1 (C-4 Ar), 128.7 (C-4 Imi),
129.7 (C-5 Imi), 130.2 (C-5 Ar), 132.2 (C-3 Ar), 138.3 (C-2 Imi), 156.7
(C-1 Ar).
Anal. Calcd for C12H15N3O: C, 66.34; H, 6.96; N, 19.34. Found: C, 66.31;
H, 7.04; N, 19.51.
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